Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 21; no. 1; pp. 337 - 8
Main Authors Ranjbar, Keivan, Moghadami, Mohsen, Mirahmadizadeh, Alireza, Fallahi, Mohammad Javad, Khaloo, Vahid, Shahriarirad, Reza, Erfani, Amirhossein, Khodamoradi, Zohre, Gholampoor Saadi, Mohammad Hasan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 10.04.2021
BioMed Central
BMC
Subjects
Adrenal Cortex Hormones - therapeutic use
Adult
Aged
Blood pressure
Clinical trials
Comparative analysis
Coronaviruses
Corticosteroid
Corticosteroids
COVID-19
COVID-19 Drug Treatment
Dexamethasone
Dexamethasone - therapeutic use
Diabetes
Disease
Drug therapy
Enrollments
Female
Health services
Hospital patients
Hospitalization
Hospitals
Humans
Hypoxia
Infectious diseases
Intervention
Iran
Length of Stay
Male
Methylprednisolone
Methylprednisolone - therapeutic use
Middle Aged
Middle East respiratory syndrome
Mortality
Pathogenesis
Patients
Prospective Studies
Randomized controlled trial
Respiration, Artificial
Respiratory diseases
Severe acute respiratory syndrome coronavirus 2
Steroids
Testing
Treatment Outcome
Vaccines
Viral diseases
Iran
COVID-19
Corticosteroid
Dexamethasone
Methylprednisolone
Randomized controlled trial
Online AccessGet full text

Cover

Abstract Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).
AbstractList Background Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. Methods In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). Results There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 [+ or -] 3.64 and 10.52 [+ or -] 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). Conclusion In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. Trial registration The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1). Keywords: Corticosteroid, COVID-19, Dexamethasone, Methylprednisolone, Randomized controlled trial
Abstract Background Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. Methods In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). Results There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). Conclusion In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. Trial registration The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).
Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).
Background Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. Methods In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). Results There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). Conclusion In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. Trial registration The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1).
Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 [+ or -] 3.64 and 10.52 [+ or -] 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone.
Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients.BACKGROUNDAlthough almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients.In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8).METHODSIn this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8).There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040).RESULTSThere were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040).In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone.CONCLUSIONIn hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone.The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).TRIAL REGISTRATIONThe trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1 ).
ArticleNumber 337
Audience Academic
Author Shahriarirad, Reza
Mirahmadizadeh, Alireza
Khodamoradi, Zohre
Khaloo, Vahid
Ranjbar, Keivan
Erfani, Amirhossein
Gholampoor Saadi, Mohammad Hasan
Fallahi, Mohammad Javad
Moghadami, Mohsen
Author_xml – sequence: 1
  givenname: Keivan
  surname: Ranjbar
  fullname: Ranjbar, Keivan
– sequence: 2
  givenname: Mohsen
  surname: Moghadami
  fullname: Moghadami, Mohsen
– sequence: 3
  givenname: Alireza
  surname: Mirahmadizadeh
  fullname: Mirahmadizadeh, Alireza
– sequence: 4
  givenname: Mohammad Javad
  surname: Fallahi
  fullname: Fallahi, Mohammad Javad
– sequence: 5
  givenname: Vahid
  surname: Khaloo
  fullname: Khaloo, Vahid
– sequence: 6
  givenname: Reza
  surname: Shahriarirad
  fullname: Shahriarirad, Reza
– sequence: 7
  givenname: Amirhossein
  surname: Erfani
  fullname: Erfani, Amirhossein
– sequence: 8
  givenname: Zohre
  surname: Khodamoradi
  fullname: Khodamoradi, Zohre
– sequence: 9
  givenname: Mohammad Hasan
  surname: Gholampoor Saadi
  fullname: Gholampoor Saadi, Mohammad Hasan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33838657$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tu1DAQhiNURA_wAlwgS9yARIod24nTC6RqOa1UVIlDby1vPNl15djB9kLLI_GUON0WuhVCKBexZr757TntFzvOOyiKxwQfEiLql5FUomlLXJES15jxkt4r9ghrSFlRynZunXeL_RjPMSaNqNoHxS6lgoqaN3vFzw-QVpd2DKCdid7mG5APSMOFGrJHxWx4gb6vTLdCk89EFNcjBJOhzodkOh8TBG80Mg6lFaAUQKUBXEK-RysfR5OUNT9Ao9np2fx1SVo0qmQyEI-QyrgZLZQLa5zOTFBO--EK77xLwVubjxlS9mFxv1c2wqPr_0Hx5e2bz7P35cnpu_ns-KTs6rZJJbAGE17XAjSrAVcCYw5Kc94LzlqoGFC-aLAGzrhQC6YWgPtG0xytFGMVPSjmG13t1bkcgxlUuJReGXll8GEp1ZS4Bdl0rK36LFs3jLFWCEYbzKumr7teA6VZ69VGa1wvBtBdzjoouyW67XFmJZf-mxSYcsHbLPDsWiD4r2uISQ4mdmCtcuDXUVY8j0LLKj69--kd9Nyvg8ulmihGeR4R9odaqpyAcb3P93aTqDyua0IFoRRn6vAvVP40DLnlDnqT7VsBz7cCpubBRVqqdYxy_unj_7OnZ9vsk9sF_F25mwnOgNgAXfAxBuhllwcumWl4lLGSYDkti9wsi8zLIq-WRU7Nqe6E3qj_I-gXknQWDg
CitedBy_id crossref_primary_10_3390_pharmaceutics16070952
crossref_primary_10_2217_fvl_2021_0244
crossref_primary_10_1016_j_imj_2022_09_004
crossref_primary_10_1371_journal_pone_0307265
crossref_primary_10_7759_cureus_51002
crossref_primary_10_1016_j_medcli_2022_03_013
crossref_primary_10_3138_cim_v46i4e03
crossref_primary_10_1097_CCE_0000000000000886
crossref_primary_10_2169_internalmedicine_7971_21
crossref_primary_10_1016_j_amsu_2021_102858
crossref_primary_10_1016_j_medcle_2022_03_020
crossref_primary_10_1097_MD_0000000000039693
crossref_primary_10_2174_0113892029291098240129113500
crossref_primary_10_1016_j_gloepi_2023_100116
crossref_primary_10_1002_acn3_51755
crossref_primary_10_1021_acsbiomaterials_2c00026
crossref_primary_10_1055_s_0042_1759505
crossref_primary_10_3389_fmed_2022_807981
crossref_primary_10_4103_1995_7645_364007
crossref_primary_10_1111_myc_13637
crossref_primary_10_1055_s_0043_1761443
crossref_primary_10_1016_j_farma_2022_11_003
crossref_primary_10_1186_s40635_024_00605_y
crossref_primary_10_1128_AAC_01275_21
crossref_primary_10_1513_AnnalsATS_202208_720OC
crossref_primary_10_1002_jmv_28751
crossref_primary_10_3390_medicina58121730
crossref_primary_10_1016_j_ijregi_2022_08_005
crossref_primary_10_3390_v14091843
crossref_primary_10_35772_ghm_2021_01121
crossref_primary_10_1002_ams2_782
crossref_primary_10_1016_j_ijid_2022_10_021
crossref_primary_10_3390_biomedicines10071548
crossref_primary_10_1016_j_ijid_2022_07_019
crossref_primary_10_7759_cureus_55725
crossref_primary_10_5812_fga_142142
crossref_primary_10_5937_sjait2106085M
crossref_primary_10_3390_v14030573
crossref_primary_10_5493_wjem_v11_i4_37
crossref_primary_10_1155_2022_6232264
crossref_primary_10_3389_fcimb_2024_1390098
crossref_primary_10_3390_ph16070924
crossref_primary_10_1093_trstmh_trac078
crossref_primary_10_1016_j_cegh_2024_101867
crossref_primary_10_1136_jim_2021_002274
crossref_primary_10_1186_s12879_021_06221_5
crossref_primary_10_1053_j_jvca_2022_05_011
crossref_primary_10_1016_j_biopha_2022_113107
crossref_primary_10_1097_BOR_0000000000000822
crossref_primary_10_3389_fimmu_2022_899559
crossref_primary_10_1016_j_intimp_2022_108689
crossref_primary_10_1097_CD9_0000000000000038
crossref_primary_10_3390_ijms23147702
crossref_primary_10_36472_msd_v11i4_1148
crossref_primary_10_4103_jfmpc_jfmpc_908_21
crossref_primary_10_5937_smclk3_35014
crossref_primary_10_1097_MJT_0000000000001507
crossref_primary_10_18632_aging_205484
crossref_primary_10_3390_brainsci12020190
crossref_primary_10_3390_jcm13123360
crossref_primary_10_1097_MJT_0000000000001506
crossref_primary_10_1007_s40124_021_00259_4
crossref_primary_10_1111_aas_14346
crossref_primary_10_1186_s12879_021_06130_7
crossref_primary_10_3390_pharmacy12040129
crossref_primary_10_1111_eci_13881
crossref_primary_10_2169_internalmedicine_0190_22
crossref_primary_10_4236_aid_2022_123042
crossref_primary_10_1007_s40121_021_00545_0
crossref_primary_10_5371_hp_2025_37_1_26
crossref_primary_10_1016_j_jiac_2022_11_008
crossref_primary_10_1093_ofid_ofab619
crossref_primary_10_3346_jkms_2023_38_e232
crossref_primary_10_1146_annurev_immunol_083122_043545
crossref_primary_10_3346_jkms_2022_37_e82
crossref_primary_10_3389_fimmu_2023_1192940
crossref_primary_10_1016_j_ppedcard_2021_101407
crossref_primary_10_1002_jcph_1929
crossref_primary_10_1055_s_0042_1759778
crossref_primary_10_5812_compreped_134897
crossref_primary_10_3390_ijms23031849
crossref_primary_10_5812_archcid_129727
crossref_primary_10_2147_IDR_S418788
crossref_primary_10_1183_13993003_01514_2022
crossref_primary_10_4103_ssj_ssj_31_23
crossref_primary_10_3389_fphar_2021_670170
crossref_primary_10_7759_cureus_26801
crossref_primary_10_2174_1568026623666221130142517
crossref_primary_10_3390_v14040670
crossref_primary_10_1186_s12879_024_09056_y
crossref_primary_10_1016_j_farma_2023_02_001
crossref_primary_10_3390_cells10123291
crossref_primary_10_1001_jamanetworkopen_2022_2973
crossref_primary_10_1177_08850666231182563
crossref_primary_10_1080_17476348_2021_1925546
crossref_primary_10_3390_ijms23137326
crossref_primary_10_1111_tid_13908
crossref_primary_10_1002_hsr2_70177
crossref_primary_10_1016_j_jinf_2023_09_008
crossref_primary_10_2174_1871526523666230822154407
crossref_primary_10_1097_BOR_0000000000000817
crossref_primary_10_1097_MD_0000000000027373
crossref_primary_10_1021_acsomega_3c00030
crossref_primary_10_1177_20499361231153546
crossref_primary_10_1002_ccr3_4931
crossref_primary_10_1186_s12890_024_03364_4
crossref_primary_10_2147_JMDH_S448786
crossref_primary_10_1016_j_biopha_2021_112276
crossref_primary_10_5867_medwave_2021_04_8198
crossref_primary_10_3390_vaccines10040614
crossref_primary_10_1111_1462_2920_15828
crossref_primary_10_15406_jlprr_2022_09_00273
crossref_primary_10_5005_jp_journals_10071_24046
crossref_primary_10_3390_jcm12082893
crossref_primary_10_5812_ijpr_137838
crossref_primary_10_5005_jp_journals_10071_24688
crossref_primary_10_1186_s41100_022_00405_8
crossref_primary_10_1186_s12879_023_08874_w
crossref_primary_10_3389_fpubh_2022_847695
crossref_primary_10_3904_kjim_2022_201
crossref_primary_10_1183_13993003_00270_2023
crossref_primary_10_3904_kjim_2022_232
crossref_primary_10_2478_pneum_2022_0013
crossref_primary_10_3389_fpubh_2021_729559
crossref_primary_10_3390_md20090586
crossref_primary_10_3390_molecules26123526
crossref_primary_10_1183_23120541_00236_2022
crossref_primary_10_23736_S0026_4806_22_08326_4
crossref_primary_10_1155_2021_8554192
crossref_primary_10_1080_00325481_2022_2033563
crossref_primary_10_1097_MD_0000000000034738
crossref_primary_10_21876_rcshci_v12i3_1264
crossref_primary_10_3390_ijms25010354
crossref_primary_10_4103_jascp_jascp_25_22
crossref_primary_10_1007_s43440_021_00341_0
crossref_primary_10_3390_cimb45040203
crossref_primary_10_1038_s41598_024_75926_9
crossref_primary_10_1371_journal_pone_0303995
crossref_primary_10_1371_journal_pone_0263471
crossref_primary_10_1124_jpet_124_002154
crossref_primary_10_1007_s40261_022_01201_2
crossref_primary_10_1007_s40121_021_00487_7
crossref_primary_10_1177_10600280211036047
crossref_primary_10_1155_2022_1248325
crossref_primary_10_4103_jrpp_jrpp_42_22
crossref_primary_10_1021_acsomega_2c01707
crossref_primary_10_7759_cureus_43179
crossref_primary_10_1177_20587384211063976
crossref_primary_10_1177_2632010X221127683
crossref_primary_10_1186_s12879_023_08280_2
crossref_primary_10_3390_antibiotics10121510
crossref_primary_10_1016_j_cyto_2024_156756
Cites_doi 10.1186/s12985-021-01532-0
10.21203/rs.3.rs-47641/v1
10.1016/S0140-6736(20)30628-0
10.1186/s40560-018-0321-9
10.1093/cid/ciaa601
10.1093/cid/ciaa1163
10.2471/BLT.20.256651
10.1016/j.biopha.2020.110267
10.1056/NEJMoa2021436
10.1097/CCM.0000000000004093
10.1186/s13033-021-00445-3
10.1093/cid/ciaa1177
10.1038/s41392-020-0158-2
10.1378/chest.124.1.12
10.1007/s00134-017-4914-x
10.1016/s0140-6736(83)90981-9
10.1586/eri.11.56
10.1007/s15010-020-01401-y
10.1001/jama.2020.17023
10.1111/eci.13458
10.4187/respcare.06314
10.1186/s40359-020-00500-7
10.1016/S0140-6736(20)30183-5
10.1183/13993003.02808-2020
10.1001/jama.2013.281053
10.1016/0091-6749(89)90381-3
10.1371/journal.pmed.0030343
10.1016/j.jcv.2020.104380
10.1186/s12879-020-05128-x
10.1101/2020.06.17.20133579
10.1177/0091270003258651
10.1016/s0162-3109(98)00025-3
10.2807/1560-7917.ES.2020.25.5.200131e
10.1164/rccm.201706-1172OC
10.1177/0049475520945446
10.1016/S1473-3099(20)30911-7
10.1016/S2666-5247(20)30173-7
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021, corrected publication 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021, corrected publication 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-021-06045-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2334
EndPage 8
ExternalDocumentID oai_doaj_org_article_7c492f549674449884370527f6cfde33
PMC8035859
A661381330
33838657
10_1186_s12879_021_06045_3
Genre Equivalence Trial
Journal Article
GeographicLocations Iran
GeographicLocations_xml – name: Iran
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c697t-e47015668ed46e028005ead55f8549e24e35b70de5458ab4abe0f7d3c69aa4423
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:28:16 EDT 2025
Thu Aug 21 14:28:12 EDT 2025
Mon Jul 21 11:03:19 EDT 2025
Fri Jul 25 05:28:28 EDT 2025
Tue Jun 17 21:08:17 EDT 2025
Tue Jun 10 20:28:03 EDT 2025
Fri Jun 27 05:00:01 EDT 2025
Fri Jun 27 04:19:29 EDT 2025
Thu Jan 02 22:37:06 EST 2025
Tue Jul 01 01:57:48 EDT 2025
Thu Apr 24 23:01:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
Corticosteroid
Dexamethasone
Methylprednisolone
Randomized controlled trial
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c697t-e47015668ed46e028005ead55f8549e24e35b70de5458ab4abe0f7d3c69aa4423
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-021-06045-3
PMID 33838657
PQID 2514350454
PQPubID 42582
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_7c492f549674449884370527f6cfde33
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8035859
proquest_miscellaneous_2511894252
proquest_journals_2514350454
gale_infotracmisc_A661381330
gale_infotracacademiconefile_A661381330
gale_incontextgauss_ISR_A661381330
gale_incontextgauss_IOV_A661381330
pubmed_primary_33838657
crossref_citationtrail_10_1186_s12879_021_06045_3
crossref_primary_10_1186_s12879_021_06045_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-04-10
PublicationDateYYYYMMDD 2021-04-10
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-10
  day: 10
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 6045_CR26
6045_CR24
GU Meduri (6045_CR31) 2018; 6
R Salvi (6045_CR35) 2020; 128
6045_CR23
P Mehta (6045_CR18) 2020; 395
6045_CR42
R Fadel (6045_CR33) 2020; 71
6045_CR41
R Shahriarirad (6045_CR16) 2020; 20
A Mirahmadizadeh (6045_CR10) 2020; 8
YM Arabi (6045_CR20) 2018; 197
6045_CR29
6045_CR28
Association WM (6045_CR30) 2013; 310
6045_CR27
ZJ Cheng (6045_CR13) 2020; 48
LJ Stockman (6045_CR19) 2006; 3
Eurosurveillance Editorial Team (6045_CR1) 2020; 25
P Vetter (6045_CR15) 2020; 1
R Shahriarirad (6045_CR8) 2020; 51
Y Wang (6045_CR39) 2020; 5
6045_CR40
6045_CR7
P Horby (6045_CR21) 2021; 384
I Darwish (6045_CR36) 2011; 9
6045_CR4
A Braude (6045_CR43) 1983; 2
6045_CR3
G Sabetian (6045_CR6) 2021; 18
M Edalatifard (6045_CR38) 2020; 56
6045_CR5
6045_CR2
DM Williams (6045_CR22) 2018; 63
AC Braude (6045_CR32) 1983; 2
6045_CR12
6045_CR34
P Vichyanond (6045_CR45) 1989; 84
DS Hui (6045_CR25) 2003; 124
B Young (6045_CR14) 2021; 21
R Shahriarirad (6045_CR11) 2021; 15
C Huang (6045_CR17) 2020; 395
DE Mager (6045_CR46) 2003; 43
MA Ashraf (6045_CR9) 2020; 21
LE Lansbury (6045_CR37) 2020; 48
T Hirano (6045_CR44) 1998; 40
34157144 - J Clin Pharmacol. 2021 Sep;61(9):1145-1148
33975548 - BMC Infect Dis. 2021 May 11;21(1):436
References_xml – volume: 18
  start-page: 58
  issue: 1
  year: 2021
  ident: 6045_CR6
  publication-title: Virol J
  doi: 10.1186/s12985-021-01532-0
– ident: 6045_CR7
  doi: 10.21203/rs.3.rs-47641/v1
– volume: 395
  start-page: 1033
  issue: 10229
  year: 2020
  ident: 6045_CR18
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(20)30628-0
– volume: 6
  start-page: 53
  issue: 1
  year: 2018
  ident: 6045_CR31
  publication-title: J Intensive Care
  doi: 10.1186/s40560-018-0321-9
– volume: 71
  start-page: 2114
  issue: 16
  year: 2020
  ident: 6045_CR33
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa601
– ident: 6045_CR42
  doi: 10.1093/cid/ciaa1163
– ident: 6045_CR12
  doi: 10.2471/BLT.20.256651
– volume: 128
  start-page: 110267
  year: 2020
  ident: 6045_CR35
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2020.110267
– volume: 384
  start-page: 693
  issue: 8
  year: 2021
  ident: 6045_CR21
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2021436
– ident: 6045_CR28
– volume: 48
  start-page: e98
  issue: 2
  year: 2020
  ident: 6045_CR37
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000004093
– volume: 15
  start-page: 19
  issue: 1
  year: 2021
  ident: 6045_CR11
  publication-title: Int J Ment Health Syst
  doi: 10.1186/s13033-021-00445-3
– ident: 6045_CR41
  doi: 10.1093/cid/ciaa1177
– volume: 5
  start-page: 57
  issue: 1
  year: 2020
  ident: 6045_CR39
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-0158-2
– volume: 124
  start-page: 12
  issue: 1
  year: 2003
  ident: 6045_CR25
  publication-title: Chest.
  doi: 10.1378/chest.124.1.12
– ident: 6045_CR24
  doi: 10.1007/s00134-017-4914-x
– volume: 2
  start-page: 995
  issue: 8357
  year: 1983
  ident: 6045_CR32
  publication-title: Lancet.
  doi: 10.1016/s0140-6736(83)90981-9
– volume: 9
  start-page: 807
  issue: 7
  year: 2011
  ident: 6045_CR36
  publication-title: Expert Rev Anti-Infect Ther
  doi: 10.1586/eri.11.56
– ident: 6045_CR4
– ident: 6045_CR2
– volume: 2
  start-page: 995
  issue: 8357
  year: 1983
  ident: 6045_CR43
  publication-title: Lancet.
  doi: 10.1016/s0140-6736(83)90981-9
– volume: 48
  start-page: 155
  issue: 2
  year: 2020
  ident: 6045_CR13
  publication-title: Infection.
  doi: 10.1007/s15010-020-01401-y
– ident: 6045_CR23
  doi: 10.1001/jama.2020.17023
– ident: 6045_CR26
  doi: 10.1111/eci.13458
– volume: 63
  start-page: 655
  issue: 6
  year: 2018
  ident: 6045_CR22
  publication-title: Respir Care
  doi: 10.4187/respcare.06314
– volume: 8
  start-page: 1
  issue: 1
  year: 2020
  ident: 6045_CR10
  publication-title: BMC Psychol
  doi: 10.1186/s40359-020-00500-7
– volume: 395
  start-page: 497
  issue: 10223
  year: 2020
  ident: 6045_CR17
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30183-5
– volume: 56
  start-page: 2002808
  issue: 6
  year: 2020
  ident: 6045_CR38
  publication-title: Eur Respir J
  doi: 10.1183/13993003.02808-2020
– volume: 310
  start-page: 2191
  issue: 20
  year: 2013
  ident: 6045_CR30
  publication-title: JAMA.
  doi: 10.1001/jama.2013.281053
– volume: 84
  start-page: 867
  issue: 6 Pt 1
  year: 1989
  ident: 6045_CR45
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/0091-6749(89)90381-3
– volume: 3
  issue: 9
  year: 2006
  ident: 6045_CR19
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0030343
– ident: 6045_CR27
– ident: 6045_CR29
– ident: 6045_CR34
  doi: 10.1016/j.jcv.2020.104380
– volume: 20
  start-page: 1
  issue: 1
  year: 2020
  ident: 6045_CR16
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-020-05128-x
– ident: 6045_CR40
  doi: 10.1101/2020.06.17.20133579
– volume: 43
  start-page: 1216
  issue: 11
  year: 2003
  ident: 6045_CR46
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270003258651
– volume: 40
  start-page: 57
  issue: 1
  year: 1998
  ident: 6045_CR44
  publication-title: Immunopharmacology.
  doi: 10.1016/s0162-3109(98)00025-3
– ident: 6045_CR5
– volume: 25
  start-page: 200131e
  issue: 5
  year: 2020
  ident: 6045_CR1
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.5.200131e
– volume: 21
  start-page: 157
  issue: 3
  year: 2020
  ident: 6045_CR9
  publication-title: J Reprod Infertil
– volume: 197
  start-page: 757
  issue: 6
  year: 2018
  ident: 6045_CR20
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201706-1172OC
– volume: 51
  start-page: 131
  issue: 1
  year: 2020
  ident: 6045_CR8
  publication-title: Trop Dr
  doi: 10.1177/0049475520945446
– volume: 21
  start-page: 20
  issue: 1
  year: 2021
  ident: 6045_CR14
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30911-7
– volume: 1
  start-page: e309
  issue: 8
  year: 2020
  ident: 6045_CR15
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(20)30173-7
– ident: 6045_CR3
– reference: 34157144 - J Clin Pharmacol. 2021 Sep;61(9):1145-1148
– reference: 33975548 - BMC Infect Dis. 2021 May 11;21(1):436
SSID ssj0017829
Score 2.6324449
Snippet Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a...
Background Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we...
Abstract Background Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 337
SubjectTerms Adrenal Cortex Hormones - therapeutic use
Adult
Aged
Blood pressure
Clinical trials
Comparative analysis
Coronaviruses
Corticosteroid
Corticosteroids
COVID-19
COVID-19 Drug Treatment
Dexamethasone
Dexamethasone - therapeutic use
Diabetes
Disease
Drug therapy
Enrollments
Female
Health services
Hospital patients
Hospitalization
Hospitals
Humans
Hypoxia
Infectious diseases
Intervention
Iran
Length of Stay
Male
Methylprednisolone
Methylprednisolone - therapeutic use
Middle Aged
Middle East respiratory syndrome
Mortality
Pathogenesis
Patients
Prospective Studies
Randomized controlled trial
Respiration, Artificial
Respiratory diseases
Severe acute respiratory syndrome coronavirus 2
Steroids
Testing
Treatment Outcome
Vaccines
Viral diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gIIOQOIDVbPxIzK0UqhapVAJa9WY5sdONtCTVZlcgfhK_khnHG22EgAu31frzajMz9szE428IeWG1l1XBU1ZDMMxEqSWz4NaZmNWpndkyrV2o8v2ojs7Ehwt5sdXqC2vCBnrgQXB7eSV0VkMWo3IhhC4KwfNUZnmtqtp5Hng-wedtkql4fgB-T2-uyBRqr4ddONcMyxGQLEYyPnFDga3_9z15yylNCya3PNDhLXIzho50f_jLt8k1394h10_i4fhd8vPEg9QXV0vv2gZMqms97ZbU-e8W-0RbiKz9a_pt3lRzimNNT_s1Eh0DCHJQ-FW88LHsGkeblkJgSMcqdNrVdB47jDQ_vKMHp-fH79hM08jL2r-hFuD41p6VC6RgdBS8oOu-BngsiF_Ax9Am5B45O3z_5eCIxVYMrFI6XzEvcrxzrQrvhPJ4HJtKsEEp6wJU4zPhuSzz1Hk8h7OlsKVP69xxmG2tgJDtPtlp4dEeEupTVboCfCTPKmG5tkJbl9rSamW9kjIhs41mTBV5yrFdxsKEfKVQZtCmAW2aoE3DE_JqnHM1sHT8Ff0WFT4ikWE7fAF2Z6LdmX_ZXUKeo7kY5NBosUjn0q773hyfnpt9iHkgEOI8_RPo86cJ6GUE1R08aGXjxQgQF3JzTZC7EyTsBNV0eGO6Ju5EvclCRIxEiwl5Ng7jTKyua323DphZoWH3zhLyYLD0UTj4CqNQMk9IPlkDE-lNR9pmHnjKi5RDMqof_Q9xPyY3srB8BQQOu2RntVz7JxAOrsqnYeX_AsgEW4Y
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgSIgXxG8KAxmExANYS2LHjnlBYzBtSGMSsGlvlhM7a6SSlKYViD-Jv5I71w2LEHur4i9R7Tvfne3zd4S8sNrnVcETVkMwzESpc2bBrTOR1olNbZnULmT5fpIHJ-LjWX4WN9z6mFa5sYnBULuuwj3ynSx4diSMezv_zrBqFJ6uxhIaV8k1pC5DrVZnw4IrBe-nNxdlCrnTgy1WmmFSAlLG5IyPnFHg7P_XMl9wTeO0yQt-aP8WuRkDSLq7lvhtcsW3d8j1o3hEfpf8PvIw9rP5wru2AcXqWk-7BXX-p8Vq0Rbia_-a_pg21ZRiW9PTfoV0xwCClSh8Fa99LLrG0aalEB7SIReddjWdxjojzS_v6N7x6eF7lmoa2Vn7N9QCHPfuWTlDIkZHwRe67luAx7T4GfwMxULukZP9D1_3DlgsyMAqqdWSeaHw5rUsvBPS46FskoMm5nldwDLTZ8LzvFSJ83gaZ0thS5_UynF421oBgdt9stVC1x4S6hNZugI8Jc8qYbm2QluX2NJqab3M8wlJN5IxVWQrx6IZMxNWLYU0a2kakKYJ0jR8Ql4N78zXXB2Xot-hwAck8myHB93i3MRpa1QldFZD56QSQuiiEFwleaZqWdXOc_jIc1QXg0waLabqnNtV35vD41OzC5EPhEOcJ_8Dffk8Ar2MoLqDjlY2Xo-A4UKGrhFye4QEe1CNmzeqa6I96s3f2TMhz4ZmfBNz7FrfrQImLTTY8GxCHqw1fRgc3MgoZK4mRI3mwGj0xi1tMw1s5UXCYUmqH13-tx6TG1mYmAICg22ytVys_BMI95bl0zCn_wDiB1R-
  priority: 102
  providerName: ProQuest
Title Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
URI https://www.ncbi.nlm.nih.gov/pubmed/33838657
https://www.proquest.com/docview/2514350454
https://www.proquest.com/docview/2511894252
https://pubmed.ncbi.nlm.nih.gov/PMC8035859
https://doaj.org/article/7c492f549674449884370527f6cfde33
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELf2ISFeEN8URmUQEg9gSGIntpEQWsumDakbKnSq9mI5sbNGKsloWjH4k_grObtpWcTYSxTFZyv23fnO9vl3CL3Q0saZoAHJwRkmLJUx0WDWCQvzQIc6DXLjo3yPkoMR-zSOxxtole6oGcD6yqWdyyc1mk3fXHz_-QEU_r1XeJG8rWGO5ZK4YAMHBRMTuom2wTJxl9FgwP6eKoA1lP62EQ9JRClbXaK5so2WofJ4_v_O2pfMVjuk8pKN2r-NbjXOJd5dSsMdtGHLu-jGoDk-v4d-DyzwZXo-s6YsQOiq0uJqho290C6TtAbf277GPyZFNsGurKhxvXBQyEAEq1Ro1V0JmVWFwUWJwXXE6zh1XOV40uQgKX5Zg_vHJ4cfSShxg9xav8MayN2-PkmnDqTRYLCTpvrmyZuQ-Sm8-kQi99Fof-9r_4A0yRpIlkg-J5Zxdys7EdawxLoD2yAGKY3jXMAS1EbM0jjlgbHupE6nTKc2yLmhUFtrBk7dA7RVQtceIWyDJDUCrCiNMqap1ExqE-hUy0TbJI47KFxxRmUNkrlLqDFVfkUjErXkpgJuKs9NRTvo1brO-RLH41rqnmP4mtJhcPsP1exMNSqteMZklEPnEs4Yk0IwyoM44nmS5cZSaOS5ExflUDZKF8Zzphd1rQ6PT9QueEXgKlEa_I_oy7BF9LIhyivoaKabqxMwXA69q0W506KEuSJrF69EV61UTUXeZ3ZQjB30bF3sarr4u9JWC08TCgnze9RBD5eSvh4ct8khkph3EG_pQGv02iVlMfFI5iKgsFyVj6__6yfoZuQVk4HTsIO25rOFfQqu4Dztok0-5vAU_bCLtnt7R5-HXb-t0vWaD89h7_QPXrtekQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIQEviO8VBhgE4gGsJbHzYSSERsfUsi8JtmlvxomdNVJJStNqwJ_EA38jd25SFiH2trcqPke173wf8d3vCHmupQ2zhHssB2eYiVSGTINZZ8LPPe3r1MuNy_LdjwZH4uNJeLJCfre1MJhW2epEp6hNleE38o3AWXYEjHs3-cawaxTerrYtNBZisWN_nEHIVr8dbgF_XwTB9ofD_oA1XQVYFsl4xqyIsXw4SqwRkcWbRS-E7QzDPIFYyQbC8jCNPWPxSkmnQqfWy2PDYbbWQiDQAaj8K4LD0cTK9P4ypcQHayvbwpwk2qhB98eSYRIEQtSEjHeMn-sR8K8lOGcKu2ma5-ze9k1yo3FY6eZCwm6RFVveJlf3miv5O-TXngVejydTa8oCBLkqLa2m1NjvGrtTa_Dn7Wt6NiqyEcWxoqb1HOGVgQgiX3grlplMq8LQoqTgjtJl7jutcjpq-poUP62h_YPj4RbzJW3QYOs3VAM53hWwdIzAj4aC7TXVV0fepOGP4adrTnKXHF0Kq-6R1RKWtkao9aLUJGCZeZAJzaUWUhtPp1pG2kZh2CN-yxmVNejo2KRjrFyUlERqwU0F3FSOm4r3yKvlnMkCG-RC6vfI8CUl4nq7B9X0VDVqQsWZkEEOi4tiIYRMEsFjLwziPMpyYzm85BmKi0LkjhJTg071vK7V8OBYbYKnBe4X597_iD5_6hC9bIjyChaa6aYcA7YLEcE6lOsdStA_WXe4FV3V6L9a_T2tPfJ0OYwzMaevtNXc0fiJBJsR9Mj9haQvNwc_nCRRGPdI3DkDnd3rjpTFyKGjJx6HEFg-uPhvPSHXBod7u2p3uL_zkFwP3CEV4JSsk9XZdG4fgas5Sx-7803Jl8tWKH8ALIiQpw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Methylprednisolone+or+dexamethasone%2C+which+one+is+superior+corticosteroid+in+the+treatment+of+hospitalized+COVID-19+patients%3A+a+triple-blinded+randomized+controlled+trial&rft.jtitle=BMC+infectious+diseases&rft.au=Ranjbar%2C+Keivan&rft.au=Moghadami%2C+Mohsen&rft.au=Mirahmadizadeh%2C+Alireza&rft.au=Fallahi%2C+Mohammad+Javad&rft.date=2021-04-10&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-021-06045-3&rft.externalDocID=A661381330
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon